Germline pathogenic variants in <i>BRCA1-,</i> <i>BRCA2-</i> , and <i>PALB2-</i> genes among Ethiopian young women and men diagnosed with breast cancer.

T Tove Ekdahl Hjelm (Department of Oncology, Södersjukhuset, Stockholm, Sweden) T Tewodros Yalew Gebremariam (Department of Pathology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia) E Endale Alemu (Department of Surgery, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia) M Mathewos Assefa Woldegeorgis (Department of Oncology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia) Åke Borg M Mahlet Fekadu Weldearegay (Department of Pathology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia) B Bethlehem Getachew Ayele (Department of Oncology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia) A Anders Kvist (Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden) A Annika Lindblom S Sara Margolin T Therese Törngren (Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden) S Senait Ashenafi (Department of Pathology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia) J Jenny Löfgren (Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden)

Abstract

10567 Background: Breast cancer incidence is rapidly increasing in low-and-middle-income countries (LMICs), where access to care is limited and survival outcome is poor. Young women and men are overrepresented among breast cancer (BC) patients diagnosed in LMICs in Sub-Saharan Africa (SSA), for reasons not yet fully understood. As hereditary cancer is more common in young women and men with BC, genetic factors may play a significant role. Even though carriers of germline pathogenic variants (PV) in the genes BRCA1 , BRCA2 , and PALB2 have a very high risk of BC, studies of PV in these genes are very limited in SSA. In order to increase knowledge, this study investigated the prevalence of PV in high-risk BC susceptibility genes in young women and men diagnosed with BC in Ethiopia. Methods: This is a descriptive cross-sectional study. One-hundred young women (age 18-39) and men (all ages) diagnosed with invasive BC were included from Departments of Oncology and Surgery at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Potential participants were given oral and written information by a trained physician, and those consenting were included in the study. Basic patient- and tumor characteristic as well as information about family history was collected. DNA was extracted from blood samples, before shipment to BRCAlab, Lund University, Sweden for genetic analysis of genes BRCA1 , BRCA2 and PALB2 , using a gene panel and next generation sequencing on an Illumina platform. Results: Genetic analysis results were available for 89 study patients. There was a high proportion (21.3%) of PV in tested genes. In total, 19 PV were found in BRCA1 (n = 7), BRCA2 (n = 8) and PALB2 (n = 4). One of the PV was in a male. There were five individuals with an identical PV in BRCA1 (c.4524G &gt; A, NM_007294.3), three individuals with identical PV in BRCA2 (c.5159C &gt; A, NM_000059.3), and two individuals with identical PV in PALB2 (c.1216delG, NM_024675.4). Two novel PV not previously reported in literature were found, BRCA1 c.5278-864_5332+621del, NM_007294.3 and PALB2 c.1169_1170del, NM_024675.4. Conclusions: This study demonstrates that germline PV in BRCA1 , BRCA2 and PALB2 are common among young women and men diagnosed with BC in Ethiopia, with over 1 out of 5 patients carrying a PV. Genetic predisposition appears to play an important role in the tumor genesis in the studied group. Multiple patients carried identical PV, which could indicate that the detected PV are founder variants. Since the majority of the patients in Ethiopia are young, and male BC seem more prevalent compared to in western countries, efforts directed to these groups and development of services for genetic testing and follow-up programs for carriers of PV should be further emphasized. This approach has the potential to reduce BC incidence, morbidity and mortality through increased awareness, risk-reducing procedures and earlier cancer detection.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 10567-10567
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (13)

T

Tove Ekdahl Hjelm

Department of Oncology, Södersjukhuset, Stockholm, Sweden

T

Tewodros Yalew Gebremariam

Department of Pathology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia

E

Endale Alemu

Department of Surgery, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia

M

Mathewos Assefa Woldegeorgis

Department of Oncology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia

Åke Borg

M

Mahlet Fekadu Weldearegay

Department of Pathology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia

B

Bethlehem Getachew Ayele

Department of Oncology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia

A

Anders Kvist

Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

A

Annika Lindblom

S

Sara Margolin

T

Therese Törngren

Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

S

Senait Ashenafi

Department of Pathology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia

J

Jenny Löfgren

Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden